Bayer and Arvinas in protein degradation venture

Bayer and Arvinas have launched a new company, Oerth Bio, to leverage Arvinas’ expertise in targeted protein degradation and Bayer’s experience in developing human therapies and agricultural technologies.

Oerth Bio will be supported by intellectual property and over $55 million in committed funding from Bayer and technology and intellectual property from Arvinas. more